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ABSTRACT
cells. Vesicular transport studies confirmed a strong inhibitory effect
of calcitriol and calcipotriol on MRP1-mediated uptake of tritiumlabeled estradiol glucuronide and leukotriene C4. In cytotoxicity assays,
MRP1-overexpressing cells exhibited hypersensitivity toward calcitriol
and calcipotriol. Such collateral sensitivity, however, was not observed
in HEK293/P-gp and HEK293/BCRP cells, although the vitamin D3
analogs inhibited calcein efflux in P-gp-overexpressing cells, and
mitoxantrone efflux in BCRP-overexpressing cells. The selective
cytotoxicity of calcitriol and calpotriol toward MRP1 over-expressing
cells can be eliminated with MRP1 inhibitor MK571. Our data indicate a
potential role of calcitriol and its analogs in targeting malignancies in
which MRP1 expression is prominent and contributes to MDR.

Introduction

and is mainly localized at the basolateral membrane. Consequently,
MRP1 plays an important role in the absorption and disposition of a
remarkably diverse set of substrates across different organs and physiologic barriers (Leier et al., 1994; Schinkel and Jonker, 2012). What makes
MRP1 relevant in MDR, however, is its ability to efflux cytotoxic anticancer agents such as doxorubicin, vincristine, and methotrexate (Cole,
2014). Overexpression of MRP1 has been associated with MDR in lung,
breast, and prostate cancers, and several types of leukemia (Burger et al.,
1994; Nooter et al., 1996; Sullivan et al., 1998; Filipits et al., 2005). In
clinics, MRP1 overexpression determines poor prognosis in a number of
cancers. In patients with localized high-risk soft tissue sarcoma of limbs
and trunk wall treated with anthracycline-based chemotherapy, MRP1
overexpression has been shown to be an independent prognostic factor for
relapse-free survival and overall survival (Martin-Broto et al., 2014).
Similarly, a large prospective study of primary neuroblastoma has shown
that MRP1 overexpression is highly predictive of event-free survival and
overall survival (Haber et al., 2006).
Collateral sensitivity is a phenomenon in which the development
of resistance toward a cytotoxic agent in the cells simultaneously
confers a greater sensitivity to an alternate agent (Szakács et al.,
2014). Collateral sensitivity is observed in cell lines overexpressing
P-gp, MRP1, and BCRP, and the possibility of exploiting this trait in
clinical cancer chemotherapy is being actively explored (Szakács
et al., 2014). The underlying mechanisms that mediate collateral
sensitivity are yet to be delineated but several putative mechanisms
have been proposed, including the generation of reactive oxygen
species, change in cellular energy levels, extrusion of essential

The development of multidrug resistance (MDR) remains a major hurdle
in chemotherapy, which is presently the standard treatment of many
metastatic and leukemic cancers. MDR is characterized by the resistance of
malignancies to structurally and mechanistically distinct anti-cancer agents,
and can arise from various physiologic changes in the cancer cells
(Gottesman et al., 2016). One of the prominent phenotypes of MDR
is the overexpression of ATP-binding cassette (ABC) membrane
transporters, which mediate MDR by active efflux of its substrate drugs
out of cancer cells, leading to sub-therapeutic level of the drugs
(Szakács et al., 2006). The main ABC transporters associated with
MDR are P-glycoprotein (P-gp/ABCB1), multidrug resistance protein
1 (MRP1/ABCC1), and breast cancer resistance protein (BCRP/ABCG2).
In humans, MRP1 is present in epithelial cells of organs such as the
lung, gastrointestinal tract, kidney, and adrenal gland (Flens et al., 1996)
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ABBREVIATIONS: ABC, ATP-binding cassette; BCRP, breast cancer resistance protein; E217bG, 17b-estradiol-17-b-(D-glucuronide); EGCG,
epigallocatechin gallate; FRET, fluorescence resonance energy transfer; GFP, green fluorescent protein; HEK293, Human embryonic kidney 293;
IC50, half-maximal inhibitory concentration; LTC4, cysteinyl leukotriene; MDCKII, Madin-Darby canine kidney II; MDR, multidrug resistance; MRP1,
multidrug resistance protein 1; MTT, thiazolyl blue tetrazolium bromide; P-gp, P-glycoprotein; Th, T helper; VDR, vitamin D receptor.
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Efflux transporters P-glycoprotein (P-gp/ABCB1), multidrug resistance protein 1 (MRP1/ABCC1), and breast cancer resistance protein (BCRP/ABCG2) can affect the efficacy and toxicity of a wide
variety of drugs and are implicated in multidrug resistance (MDR).
Eight test compounds, recently identified from an intramolecular
FRET-based high throughput screening, were characterized for their
interaction with MRP1. We report that the active metabolite of vitamin
D3, calcitriol, and its analog calcipotriol are selectively cytotoxic to
MRP1-overexpressing cells, besides inhibiting transport function of
P-gp, MRP1, and BCRP. Calcitriol and calcipotriol consistently displayed a potent inhibitory activity on MRP1-mediated doxorubicin and
calcein efflux in MRP1-overexpressing H69AR and HEK293/MRP1
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Materials and Methods
Chemicals. Calcitriol, calcipotriol, MK571, epigallocatechin gallate (EGCG),
hyperoside, LTC4, meropenem, mesalamine, nitazoxanide, and vincristine were
purchased from Cayman Chemical (Ann Arbor, MI). AMP, ATP, doxorubicin,
estradiol 17-(b-D-glucuronide) (E217bG), mitoxantrone, poly-D-lysine, thiazolyl
blue tetrazolium bromide (MTT), and verapamil were procured from Sigma-Aldrich
(St. Louis, MO). Apigenin and Ko143 were purchased from Tocris Bioscience
(Avonmouth, Bristol, UK). Calcein-AM was obtained from Corning Life Sciences
(Corning, NY). [6,7-3H]E217bG (49.9 Ci mmol21) and [14, 15, 19, 20-3H]LTC4
(177.6 Ci mmol21) were purchased from PerkinElmer (Waltham, MA).
Cell Lines and Cell Culture. H69 and H69AR cells were procured from
ATCC (Manassas, VA). HEK293T cells were a gift from Dr. Adam Hoppe
(SDSU, Brookings, SD). HEK293/pcDNA3.1, HEK293/MRP1, HEK293/P-gp,
and HEK293/BCRP were kindly gifted by Dr. Suresh V. Ambudkar (NIH,
Bethesda, MD) and were maintained as described before (Müller et al., 2002).
MDCKII, MDCKII/P-gp, and MDCKII/BCRP cells were kindly provided by
Dr. Alfred Schinkel (Netherlands Cancer Institute, Amsterdam, The Netherlands).
HEK293 and MDCKII cell lines were grown in DMEM (GE Healthcare,
Marlborough, MA) supplemented with 10% FBS. H69 cell lines were cultured
in RPMI 1640 (ATCC) media supplemented with 10% FBS. H69AR cells were
monthly exposed to 0.8 mM doxorubicin and cultured without drug for 1 week
before use in experiments. Cells were cultured at 37C in a humidified incubator
set at 5% CO2.
Western Blot Analysis. Cell lysates were prepared in RIPA buffer (ThermoFisher Scientific, Waltham, MA) supplemented with 1 Halt Protease Inhibitor
Cocktail (ThermoFisher Scientific). Protein concentration was determined using
Pierce BCA Protein Assay (ThermoFisher Scientific). Cell lysates (20 mg protein)
were electrophoresed on 7.5% Mini-PROTEAN TGX gels (BioRad, Hercules,
CA) and transferred onto Immobilon PVDF membranes (EMD Millipore,
Burlington, MA). Membranes were blocked for 1 hour at room temperature and
incubated overnight at 4C with monoclonal anti-MRP1 antibody (IU5C1;
ThermoFisher Scientific) or anti-a-tubulin antibody (Sigma-Aldrich) at 1:250 and
1:5000 dilutions, respectively. Secondary antibody incubation was performed

using horseradish peroxidase-conjugated goat anti-mouse IgG (H + L) (ThermoFisher
Scientific) for 1 hour at room temperature. Target proteins were detected using
Western Lightning Plus-ECL, Enhanced Chemiluminescence Substrate (PerkinElmer)
and an OMEGA LUM G Imaging System (Aplegen, Pleasanton, CA). For protein
expression comparison, protein band density was analyzed using the Image Studio
Lite (LI-COR Biotechnology, Lincoln, NE) software and corrected for uneven
sample loading and transfer using a-tubulin as the loading control.
Calcein, Mitoxantrone and Doxorubicin Accumulation Assay. Calcein
was used as the fluorescent substrate for accumulation assays studying MRP1 and
P-gp, whereas mitoxantrone was used for BCRP {Peterson, 2017 #112}. Excitation
was performed at 488 nm for calcein and mitoxantrone, with emission bands of
533/30 and .670 nm, respectively. Fluorescence intensity was represented as the
mean value of 10,000 events. Experiments were done in duplicate. Doxorubicin
accumulation assay was performed as described previously {Peterson, 2017 #112}.
Cytotoxicity Assay. Cell sensitivity to test compounds was analyzed using the
MTT colorimetric assay. HEK293 and H69 cell lines were plated in 96-well plates
(CellBIND; Corning) at 5  103 and 2.5  104 cells per well, respectively, in
100 ml culture medium. The next day, 100 ml of test compound of varying
concentrations prepared in culture medium were added to the cells. DMSO
concentration was maintained at 0.5%. For drug combination treatment in
HEK293/P-gp and HEK293/BCRP cells, 50 ml of calcitriol, calcipotriol, or
control compounds were added and incubated for 1 hour before 50 ml of
cytotoxic drugs (vincristine or mitoxantrone) were added. Cells were incubated for
72 (HEK293 cell lines) or 96 hour (H69 cell lines). At the end of the incubation
period, 100 ml of culture medium was carefully removed and cells were treated
with MTT (0.45 mg/ml) for 4 hour. The formazan crystals were dissolved by the
addition of 100 ml 15% SDS containing 10 mM HCl and absorbance at 570 nm
were recorded using a Hidex Sense Beta Plus plate reader (Turku, Finland).
Membrane Vesicular Transport Assay. Plasma membrane vesicles were
prepared as previously described with modifications {Iram and Cole, 2011;
Peterson, 2017 #112 and Loe et al., 1996 #35}. ATP-dependent transport of
[3H]E217bG and [3H]LTC4 into the inside-out membrane vesicles was measured
by a rapid filtration technique {Loe et al., 1996 #35 and Peterson, 2017 #112}.
RNA Isolation and qPCR Analysis. Cells treated with calcitriol or calcipotriol
for 72 hour were pelleted by centrifugation and stored for RNA isolation. Total RNA
was isolated using the Ambion TRIzol plus RNA purification kit (ThermoFisher
Scientific). To rid the freshly prepared total RNA of possible DNA contamination, DNase1 enzyme treatment was performed using the Turbo DNA-free kit
(ThermoFisher Scientific). The concentration and integrity of RNA was determined
using the 260/280 ratios generated by a Nano-drop UV spectrophotometer. cDNA
synthesis was done with the recombinant M-MuLV-based ProtoScript II First strand
cDNA synthesis kit (New England Biolabs, Ipswich, MA) using 1 mg of the total
RNA as starting material. Gene-specific primers were designed using the Primer3
(NIH) and synthesized by Eurofins Scientific (Louisville, KY). Table 1 shows the
list of primer sequences. qPCR was performed using Luna Universal Probe qPCR
Master Mix (New England Biolabs) according to the manufacturer’s
instructions in a QuantStudio3 Real-Time PCR System (Thermo Fisher
Scientific). The three-step PCR conditions used are as follows: 95C denaturation
for 1.2 minute, 45 cycles of (annealing at 60C for 20 second, extension at 72C
for 30 second), and denaturation for 10 second. This was followed by melting
curve stage from 60 to 95C for 20 second while scanning for fluorescence.
Relative quantitation was performed using the 2 2ΔΔCt method and data were
normalized against housekeeping genes, b-actin and ubiquitin conjugating enzyme
(UbCE), of respective samples. The relative messenger RNA (mRNA) expression
level was calculated as a fraction of the untreated cells.
Statistical Analysis. Statistical analyses were done with IBM SPSS Statistics
19 (IBM, Armonk, NY). The differences between mean values were determined
with linear mixed model analysis. For multiple comparisons, Sidak correction was
performed.

Results
Effects of Test Compounds on MRP1 Activity in Cell-Based
Assays. We previously engineered a two-color MRP1 protein that reports
intramolecular FRET changes as an index of structural changes in the
nucleotide binding domains of MRP1 (Iram et al., 2015). Specifically, a
structural change that brings the nucleotide binding domains closer
together increases FRET efficiency from a basal to higher level, reflecting
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endogenous substrate, and membrane perturbation in the resistant cells
(Pluchino et al., 2012).
Calcitriol (1,25-dihydroxyvitamin D3), the active metabolite of
vitamin D3, is a potent hormone that regulates numerous physiologic
processes in human body. Traditionally, calcitriol is recognized for its
role in bone health through action on calcium and phosphorus absorption
(Holick, 2007). In recent years, however, accumulating data has indicated
its non-skeletal functions in many chronic diseases (Holick, 2007). In
cancer, multiple lines of evidence from epidemiologic and preclinical
studies generally suggest a positive role of calcitriol in reducing cancer
risk and progression, but evidence from randomized clinical trials has
been lacking or inconclusive (Kupferschmidt, 2012; Feldman et al.,
2014). Nevertheless, the interest in utilizing calcitriol for the prevention
and improvement of cancer and other diseases remains high and a number
of large-scale clinical trials are currently underway to determine the
effects of calcitriol on these major diseases (Kupferschmidt, 2012).
Previously, we engineered a “two-color MRP1” by fusing green
fluorescent protein (GFP) and a red fluorescent protein to the nucleotidebinding domains of MRP1 (Iram et al., 2015). The genetically encoded
two-color MRP1 recombinant protein can measure intramolecular fluorescence resonance energy transfer (FRET) efficiency as an index of protein
conformational changes upon ligand binding in live cells. Using this
approach, a compound library was screened and eight compounds were
identified that directly interact, bind and induce a conformational change in
the structure of MRP1 (Iram et al., 2015). In the present work, we evaluated
the effects of the hit compounds on MRP1 transport activity using different
substrates of MRP1 in various cell- and membrane-based assays. We
placed our focus on calcitriol and calcipotriol after initial characterization
owing to their strong modulatory effects on MRP1 and discovered their
selective cytotoxic effect on MRP1-expressing cells.
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TABLE 1
Primer sequences
Gene

Forward primer

Reverse primer

MRP1
B-Actin
Ubiquitin CE

AGGACACGTCGGAACAAGTC
CATGTACGTTGCTATCCAGGC
ATGCGGGACTTCAAGAGGAG

GGAAGTAGGGCCCAAAGGTC
CTCCTTAATGTCACGCACGAT
AAAATGACCGCGTTCCACAC

inhibitor. Calcitriol and calcipotriol (50 mM) increased calcein accumulation to levels comparable to that of MK571. In contrast, droperidol,
meropenem, nitazoxanide, hyperoside, EGCG, and mesalamine did not
significantly increase calcein accumulation in H69AR cells. On the other
hand, no modulatory effect was observed for any of the test compound in
the parental H69 cell lines. We also performed the calcein efflux assay
using HEK293 cells. In HEK293/MRP1 cells, treatment with MK571
resulted in ;fourfold increase of calcein accumulation (Fig. 2C). Similar
calcein accumulation was observed with calcitriol and calcipotriol
treatment, whereas a ;2.5-fold enhancement in calcein accumulation
was seen in treatment with droperidol. Meropenem, nitazoxanide,
hyperoside, EGCG, and mesalamine treatments did not exhibit a
significant effect on calcein accumulation in HEK293/MRP1 cells.
As expected, no or very weak modulatory effect was observed for the
test compounds in the control HEK293/pcDNA3.1 cell lines.
Next, the effects of the hit compounds on MRP1 transport activity
were evaluated by detecting the accumulation of the fluorescent anticancer drug, doxorubicin, a well-known substrate of MRP1. HEK293T
cells were transiently transfected with MRP1-GFP vector and confocal
microscopy was used to visualize the inhibitory effect of the test
compounds on MRP1-mediated doxorubicin efflux in live cells. As
shown in Fig. 2D, cells treated with DMSO (vehicle) showed high
doxorubicin accumulation in the nuclei of non-transfected cells, while
doxorubicin fluorescence was very low or undetectable in cells
expressing MRP1-GFP. MRP1-mediated efflux of doxorubicin was
blocked by MK571 treatment (50 mM). Among the test compounds

Fig. 1. Chemical structures of the test compounds.
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the closer proximity of the fluorescent tags. A FRET-based screening of
the NIH Clinical Collection compound library identified eight hits that
significantly altered the fluorescent lifetime of the donor (Iram et al.,
2015). The hit compounds included EGCG (antioxidant), hyperoside
(antibiotic and antioxidant), calcitriol and calcipotriol (vitamin D analogs),
mesalamine (anti-inflammatory), meropenem (antibiotic), nitazoxanide
(antiprotozoal), and droperidol (antipsychotic) (Fig. 1). In the present
study, we employed different cell- and membrane-based functional assays
to further characterize the effects of these compounds on MRP1 activity.
To investigate the interaction of the test compounds with MRP1, we
used MRP1-overexpressing cell lines H69AR and HEK293/MRP1.
Expression levels of MRP1 in these cell lines as compared with their
respective parental cell lines was verified by immunoblot analysis using
whole cell lysates as shown in Fig. 2A. As expected, high levels of
MRP1 were present in H69AR and HEK293/MRP1 cells, whereas the
endogenous levels of MRP1 in the respective parental cell lines were not
detectable. Similar levels of a-tubulin in all lysate samples demonstrated
equal sample loading. First, we performed calcein efflux assay to determine
the inhibitory potency of the test compounds. Calcein-AM, a wellknown substrate for P-gp and MRP1, is a cell permeable and nonfluorescent compound that turns into highly fluorescent molecule after
the acetoxymethyl ester (AM) moiety is cleaved off by cellular esterases.
The intracellular accumulation of fluorescent calcein with or without the
presence of test compounds was detected using flow cytometry. As
shown in Fig. 2B, accumulation of calcein was enhanced ;10-fold in
H69AR cells with MK571 treatment (50 mM), a widely used MRP1

Collateral Sensitivity of MRP1-Overexpressing Cells
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Fig. 2. Effects of test compounds on MRP1 activity in cell-based assays. (A) Immunoblot analysis of whole cell lysates prepared from indicated cell lines was performed as
described in the Materials and Methods section. (B and C) Calcein accumulation assay. Control and MRP1-overexpressing cells were pre-treated with 50 mM MK571 or test
compounds for 10 minute before incubation with 25 nM calcein-AM at 37C for 30 minute. Fluorescence intensity of intracellular calcein was detected using flow cytometry,
with excitation and emission wavelengths of 480 and 533/30 nm, respectively. Data are combined from three experiments (performed in duplicate) and presented as mean 6
S.E.M. *P , 0.05; ***P , 0.001 compared with control of each cell line, calculated using linear mixed model and Sidak post hoc test. (D) Doxorubicin accumulation assay.
HEK293T cells transiently transfected with MRP1-GFP (green) were pre-treated with 50 mM test compounds, before incubation with doxorubicin (red) at 37C for 1 hour.
Images were acquired using confocal microscopy. GFP and doxorubicin were excited at 488 nm, and detected at 475/42 and 605/64 nm, respectively.
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(50 mM), calcitriol, calcipotriol, and droperidol treatments exhibited
high nuclear accumulation of doxorubicin similar to MK571 treatment.
In contrast, treatment with meropenem, nitazoxanide, hyperoside, EGCG,
or mesalamine showed very low or undetectable levels of doxorubicin in
the nuclei of MRP1-GFP expressing cells, although MRP1 was clearly
localized at the plasma membrane.
Effects of Test Compounds on MRP1 Activity in Membrane
Vesicle-Based Assays. Apart from the abovementioned cell-based
assays, we also employed membrane-based vesicular uptake assay to
evaluate the effects of test compounds on MRP1-mediated transport of
endogenous organic anions. E217bG (a glucuronide conjugate) and
LTC4 (a glutathione conjugate) are prototypical substrates of MRP1.
Membrane vesicles were prepared from HEK293/pcDNA3.1 and
HEK293/MRP1 cells. Transport activities were measured using
[3H]E217bG and [3H]LTC4 as MRP1 substrates, and test compound
treatment was performed at 10 and 50 mM. As shown in Fig. 3A,
transport of [3H]E217bG was reduced by ;95% with 10 mM MK571
treatment and no active transport was detectable with 50 mM MK571
treatment. Among the test compounds, calcitriol, calcipotriol, and
EGCG displayed significant inhibitory activity. For instance, 10 mM
treatment with calcitriol, calcipotriol, or EGCG decreased [3H]E217bG
transport by ;50%, 40%, or 35%, respectively (Fig. 3A). In contrast, no
significant [3H]E217bG transport inhibition was observed with 10 mM
treatments of droperidol, meropenem, nitazoxanide, hyperoside, or mesalamine. Similarly, when MRP1-mediated [3H]LTC4 transport activity was
measured, 10 mM treatment with calcitriol, calcipotriol, droperidol, hyperoside, or EGCG decreased transport by ;65%, 50%, 35%, 45%, or 65%,
respectively (Fig. 3B). Among the hit compounds, calcitriol and calcipotriol
exhibited strong inhibition for all tested substrates in cell- and membranebased assays. Therefore, we performed concentration-dependent inhibition
experiments to determine their relative potencies. The concentrationresponse curves generated using [3H]E217bG as substrate showed a typical
sigmoidal shape (Fig. 3, C and D), with IC50 values of 8.6 6 1.4 and 12.2 6
0.8 mM for calcitriol and calcipotriol, respectively (Table 2).

Collateral Sensitivity of MRP1-Overexpressing Cells Toward
Calcitriol and Calcipotriol. Based on the strong modulatory effect
observed for calcitriol and calcipotriol in both the cell- and membranebased assays, we decided to focus on these vitamin D3 analogs in our
further studies. Additionally, the importance of calcitriol as an essential
hormone and the strong interest of applying calcitriol in the clinical
settings of various major diseases including cancer prompted us to
further investigate their interactions with MRP1. Initially, we intended
to test their ability to reverse MRP1-related drug resistance toward
anti-cancer agents such as etoposide and vincristine using the MTT
cytotoxicity assay. However, in our preliminary studies to determine an
appropriate concentration to be used in the resistance reversal assay, we
unexpectedly observed a hypersensitivity of MRP1-overexpressing cells
toward calcitriol and calcipotriol. Data from the subsequent cytotoxic
TABLE 2
Reaction parameters derived from the cytotoxicity and membrane vesicular
transport assays
IC50 (mM)a

Assay
Cytotoxicity

H69
H69AR (control)
H69AR + 10 mM MK571
H69AR + 50 mM MK571
HEK293/pcDNA3.1
HEK293/MRP1 (control)
HEK293/MRP1+ 10 mM MK571
HEK293/MRP1+ 50 mM MK571
HEK293/P-gp
HEK293/BCRP
Membrane vesicular transport
E217bG

Calcitriol

29.0
11.0
16.4
61.6
33.4
8.9
11.7
35.3
43.1
31.3

6
6
6
6
6
6
6
6
6
6

1.2*
0.7
1.9
1.2**
2.5**
1.3
1.1
4.0**
4.3**
5.3**

9.0 6 1.3

Calcipotriol

23.9
8.5
15.0
42.4
23.3
6.0
16.5
27.5
37.9
20.8

6
6
6
6
6
6
6
6
6
6

0.5*
1.0
1.1*
1.0**
3.7
1.8
0.4*
0.2**
5.1**
2.7*

12.3 6 0.1

Mean 6 S.E.M. of n = 3 independent experiments.
*P , 0.05; **P , 0.01 significantly different then the control in each cell line group,
calculated using linear mixed model with Sidak post hoc test.
a
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Fig. 3. Effects of test compounds on MRP1
activity in membrane vesicle-based assays. (A
and B) Inside-out membrane vesicular uptake
assay. Membrane vesicles (2 mg protein) prepared from HEK293/pcDNA3.1 (vector control) and HEK293/MRP1 cells were incubated
with 10 or 50 mM test compounds and (A)
400 nM/20 nCi [3H]E217bG or (B) 50 nM/2
nCi [3H]LTC4 at 37C for 1 minute. MRP1
uptake activity was determined by measuring
the radioactivity retained on collected membrane vesicles using liquid scintillation counting. Data are combined from $3 experiments
(performed in triplicate) and presented as mean
6 S.E.M. #, value below background; **P ,
0.01; ***P , 0.001 compared with control,
calculated using linear mixed model and Sidak
post hoc test. Concentration-dependent inhibition of MRP1 activity by calcitriol (C) and
calcipotriol (D). MRP1-mediated uptake of [3H]
E217bG was performed by incubating HEK293/
MRP1 membrane vesicles (2 mg protein) with
various concentrations of calcitriol or calcipotriol.
Data are representative of three experiments and
presented as mean 6 S.D. (n = 3).

Collateral Sensitivity of MRP1-Overexpressing Cells

performed qPCR and Western blot analysis on HEK293/MRP1 and
H69AR treated with calcitriol and calcipotriol at 1 and 10 mM. The
mRNA and protein expression levels of MRP1 in both cell lines were not
significantly altered by 1 mM calcitriol and calcipotriol (data not shown).
However, at 10 mM concentration, calcitriol treatment increased the
mRNA levels of MRP1 in HEK293/MRP1 cells but not in H69AR cells
(Fig. 5A). In contrast, at 10 mM concentration, calcipotriol treatment
increased the mRNA levels of MRP1 in H69AR cells but not in
HEK293/MRP1 cells. As shown in Fig. 5C, protein expression levels
of MRP1 were decreased significantly in H69AR cells but not in
HEK/MRP1 cells with 10 mM calcitriol treatment. However, calcipotriol
treatment at 10 mM concentration did not significantly change MRP1
expression levels in both cell lines.
Inhibition of P-gp and BCRP Transport Activity by Calcitriol
and Calcipotriol. Calcitriol and calcipotriol have not been reported to
directly interact with ABC transporters. Therefore, we were interested
to investigate if they interact with P-gp and BCRP. We first tested if calcitriol
and calcipotriol can modulate the transport function of P-gp and BCRP. To
this end, we examined the accumulation of calcein (a P-gp substrate) and
mitoxantrone (a BCRP substrate) in P-gp- and BCRP-overexpressing cells,

Fig. 4. Collateral sensitivity of MRP1-overexpressing cells toward calcitriol and calcipotriol. H69 and H69AR cells were treated with increasing concentrations of calcitriol
or calcipotriol in the absence or presence of MK571 for 96 hour (A). Similar experiments were performed using calcitriol or calcipotriol in HEK293/pcDNA3.1 and
HEK293/MRP1 cells in the absence or presence of MK571 for 72 hour (B). Cell viability was evaluated with MTT assay. Data are representative of three experiments and
expressed as mean 6 S.D. (n = 3).

Downloaded from dmd.aspetjournals.org at ASPET Journals on July 2, 2019

studies revealed a concentration-dependent cytotoxic effect of calcitriol and
calcipotriol, with IC50 values of 11.0 6 0.7 and 8.5 6 1.0 mM, respectively,
in MRP1 over-expressing H69AR cells (Fig. 4A; Table 2). In contrast, we
observed ;threefold higher IC50 values for calcitriol and calcipotriol in the
parental H69 cells. In HEK293/MRP1 cells, calcitriol and calcipotriol also
exhibited a concentration-dependent cytotoxic effect, with IC50 values of 8.9
6 1.3 and 6.0 6 1.8 mM, respectively, which are ;fourfold lower than
those observed in the HEK293/pcDNA3.1 control cells (Fig. 4B; Table 2).
To test whether the observed collateral sensitivity is dependent on MRP1
transport function, we measured the cytotoxicity of calcitriol and calcipotriol
treatments in MRP1 over-expressing H69AR and HEK293/MRP1 cells in
the presence of 10 and 50 mM MK571 (MRP1 inhibitor). Our results
showed that collateral sensitivity of MRP1 over-expressing cell lines
toward calcitriol and calcipotriol can be eliminated by MRP1 inhibitor
MK571 (Fig. 4; Table 2). By using inhibitor at 10 mM (partial MRP1
inhibition) and 50 mM (complete MRP1 inhibition) the data indicated
that collateral sensitivity is proportional to the amount of active MRP1.
Effects of Calcitriol and Calcipotriol on MRP1 mRNA and
Protein Expression Levels. To investigate if calcitriol and calcipotriol
can affect the mRNA and protein expression levels of MRP1, we

1861

1862

Tan et al.

respectively, using flow cytometry. As shown in Fig. 6, A and B, treatment
with 25 mM verapamil, a standard P-gp inhibitor, resulted in enhancement of calcein accumulation by 21- and 14-fold in HEK293/P-gp and

Discussion
In the present study, we report for the first time that the active
metabolite of vitamin D3, calcitriol, and its analog calcipotriol, cause
selective cytotoxicity in MRP1-overexpressing, but not P-gp- and
BCRP-overexpressing cell lines. In addition, we demonstrate an
inhibitory activity of calcitriol and calcipotriol on the transport function
of MRP1, P-gp, and BCRP, which are prominently involved in MDR
and drug disposition. Our results show that collateral sensitivity of
MRP1 over-expressing cell lines toward calcitriol and calcipotriol can be
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Fig. 5. Effects of calcitriol and calcipotriol on the mRNA and protein expression of
MRP1. Cells were treated with DMSO, calcitriol, or calcipotriol (10 mM) for 72 hour. (A)
mRNA levels of parental (HEK293 and H69) cells and MRP1-overexpressing cells
(HEK293/MRP1 and H69AR) were quantified using qPCR as described in the Materials
and Methods section. Data are combined from three experiments (each performed in
triplicate) and presented as mean 6 S.E.M. *P , 0.05; ***P , 0.001 compared with
control, calculated using linear mixed model and Sidak post hoc test. (B) Immunoblot
analysis of whole cell lysates prepared from indicated cell lines with indicated treatments
was performed as described in the Materials and Methods section. Data are representative
of three experiments. Mean MRP1 protein expression (6S.E.M., n = 3) shown as a fold
change of the DMSO-treated control is shown in (C). Protein band density was analyzed
using the Image Studio Lite (LI-COR Biotechnology) software and corrected for uneven
sample loading and transfer using a-tubulin as the loading control. *P , 0.05; ***P ,
0.001 compared with control, calculated using linear mixed model and Sidak post hoc test.

MDCKII/P-gp cells, respectively. Calcitriol at 10 and 50 mM increased
calcein accumulation in HEK293/P-gp cells by 2.3- and 7.8-fold, and
in MDCKII/P-gp cells by 2.0- and 7.6-fold, respectively. Similarly,
calcipotriol at 10 and 50 mM enhanced calcein accumulation by 2.8- and
7.5-fold in HEK293/P-gp cells, and 3.2- and 7.3-fold in MDCKII/P-gp
cells, respectively. On the other hand, no or very weak modulatory effect
was observed for calcitriol or calcipotriol in both parental cell lines.
Next, the inhibitory effect of calcitriol and calcipotriol on BCRP-mediated
efflux was tested. As illustrated in Fig. 6, C and D, treatment with 5 mM
Ko143, a widely used BCRP inhibitor, enhanced mitoxantrone accumulation by 5.1- and 5.7-fold in HEK293/BCRP and MDCKII/BCRP
cells, respectively. Calcitriol at 10 and 50 mM increased mitoxantrone
accumulation in HEK293/BCRP cells by 4.3- and 5.9-fold, and in
MDCKII/BCRP cells by 3.0- and 5.3-fold, respectively. Likewise, calcipotriol at 10 and 50 mM resulted in higher mitoxantrone accumulation
by 4.6- and 7.0-fold in HEK293/BCRP cells, and 3.4- and 6.2-fold in
MDCKII/BCRP cells, respectively. As expected, no or very weak
modulatory effect was observed for calcitriol or calcipotriol in both
parental cell lines.
Lack of Collateral Sensitivity in P-gp- and BCRP-Overexpressing
Cells Toward Calcitriol and Calcipotriol. Collateral sensitivity has been
observed in cells overexpressing P-gp and BCRP (Szakács et al., 2014).
To investigate if the collateral sensitivity effect observed for MRP1overexpressing cells toward calcitriol and calcipotriol is also inherent in
cells overexpressing P-gp and BCRP, two other ABC transporters that
are prominently involved in MDR, we examined the cytotoxic effect of
calcitriol and calcipotriol on HEK293 cells overexpressing P-gp and
BCRP. As shown in Fig. 7, the sensitivity of HEK293/P-gp and
HEK293/BCRP cells toward calcitriol and calcipotriol was similar to that
of HEK293/pcDNA3.1 cells. The lack of sensitivity toward calcitriol and
calcipotriol is also reflected in their relatively close or higher IC50 values as
compared with that of HEK293/pcDNA3.1 cells (Table 2).
Effects of Calcitriol and Calcipotriol on Drug Sensitivity of
HEK293/P-gp and HEK293/BCRP Cells. Following the observation
that calcitriol and calcipotriol do not cause collateral sensitivity in
HEK293/P-gp and HEK293/BCRP cells, we investigated if calcitriol
and calcipotriol can reverse drug resistance of the cells toward cytotoxic
P-gp and BCRP substrates. HEK293/P-gp and HEK293/BCRP cells
were treated with anticancer drugs vincristine and mitoxantrone, respectively, in the presence and absence of 10 mM calcitriol and
calcipotriol. Verapamil (25 mM) and Ko143 (1 mM) were used
as positive controls for P-gp and BCRP, respectively. As shown in
Fig. 8, HEK293/P-gp and HEK293/BCRP cells exhibited significant drug resistance as compared with the vector control cell line
HEK293/pcDNA3.1. Treatment with verapamil and Ko143 in
HEK293/P-gp and HEK293/BCRP cells, respectively, reversed the
resistance of the cells toward the anticancer agents. IC50 values of the
treatments are shown in Table 3. In both cell lines, co-treatment with
10 mM calcitriol significantly reversed the resistance of the cells to a
certain extent. However, no significant reversal was observed in cells
co-treated with 10 mM calcipotriol.
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eliminated by MRP1 inhibitor MK571. We initiated the present work as
a follow up of our previous study, which used a genetically-engineered
two-color MRP1 for high-throughput identification of potential MRP1
substrates and modulators (Iram et al., 2015). The two-color MRP1
reports ligand-induced structural changes through changes in intramolecular FRET efficiency. Such structural approach has also been
successfully applied for the discovery of activator/inhibitor candidates of the P-type sarco/endoplasmic reticulum calcium ATPase
(Gruber et al., 2014).
High throughput screening of the NIH Clinical Collection compound
library using the MRP1 FRET-based reporter identified eight compounds that directly interact, bind and induce a conformational change in
the structure of MRP1 (Iram et al., 2015). However, this FRET-based
screening does not provide any information about the biochemical
nature of interaction of the hit molecules with MRP1. The identified
compounds from this screen could be a substrate, inhibitor, activator or
a molecule that simply interacts with MRP1 to stimulate transport of a
substrate or binds with the transporter for unknown reasons or could be a
false hit due to non-specific interaction with MRP1. In the present work,
we evaluated the effects of the hit compounds on MRP1 transport activity
using different substrates of MRP1 in various cell- and membrane-based
assays. Based on our results, we identified calcitriol and calcipotriol as
inhibitors of MRP1. Both agents showed strong inhibition of MRP1
activity for all substrates tested. We also discovered that calcitriol and

calcipotriol inhibit transport activity of P-gp and BCRP. However, further
work is needed to determine whether calcitriol and calcipotriol are also
substrates of these transporters. Droperidol exhibited both substrate
selective and cell line specific inhibition of MRP1. It showed no inhibition
of E217bG and LTC4 by MRP1 while strong inhibition was observed for
the anti-cancer drug doxorubicin. There is plenty of data to indicate that
MRP1 has multiple distinct substrate binding sites. Hydrophobic drugs are
predicted to bind on the top half of the binding pocket while the anionic
compounds are predicted to bind in the lower half closer to the membrane
interface. Substrate selective inhibition of MRP1 by Droperidol is of high
interest because it can block the efflux of cytotoxic drug doxorubicin to
improve its efficacy while keeping the transport of important physiologic
substrates (E217bG and LTC4) unaltered. Droperidol showed moderate
inhibition of calcein efflux in HEK/MRP1 cells while no inhibition was
observed for calcein efflux in H69AR cells. It is not uncommon to observe
cell line specific effects of a drug. H69AR was derived by long-term
exposure to a drug while HEK/MRP1 was developed by transfection and
they can be very different in terms of their molecular profile and membrane
dynamics. The flavonoids EGCG and hyperoside showed inhibition of
E217bG and LTC4 transport by MRP1 while no inhibition was observed
for calcein and doxorubicin (Figs. 2 and 3). EGCG is a known substrate of
MRP1 (Hong et al., 2003). The inhibition of endogenous organic anion
substrates E217bG and LTC4 by EGCG and hyperoside is probably due to
transport competition when the two substrates compete for the same
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Fig. 6. Calcitriol and calcipotriol inhibit P-gp- and BCRP-mediated efflux. Control, P-gp-overexpressing HEK293 (A) or MDCKII (B), and BCRP-overexpressing HEK293
(C) or MDCKII (D) cells were pre-treated with calcitriol and calcipotriol at 37C for 10 minute before incubation with 25 nM calcein-AM (A and B) or 5 mM mitoxantrone
(C and D) for 30 minute. Verapamil and Ko143 were used as positive controls for P-gp and BCRP inhibition, respectively. Intracellular accumulation of calcein and
mitoxantrone was quantified by flow cytometry. Data are combined from three experiments (performed in duplicate) and presented as mean 6 S.E.M. *P , 0.05; **P ,
0.01; ***P , 0.001 compared with control, calculated using linear mixed model and Sidak post hoc test.
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Fig. 7. P-gp- and BCRP-overexpressing cells do not show collateral sensitivity
toward calcitriol and calcipotriol. HEK293/pcDNA3.1, HEK293/P-gp, and
HEK293/BCRP cells were treated with increasing concentrations of calcitriol (A)
or calcipotriol (B) for 72 hour. Cell viability was evaluated with MTT assay. Data
are representative of three experiments and expressed as mean 6 S.D. (n = 3).

binding site or if the binding sites are overlapping. Mesalamine
only showed weak inhibition for LTC4. Two of the hit compounds,
nitazoxanide and meropenem, which did not show inhibition on any
tested substrates, are anticipated to be substrates of MRP1 with a distinct
substrate binding site. They could also be false hits from the FRET-based
screening. Further work is needed to verify their interaction with MRP1.
Generally, among ABC drug transporters, P-gp is considered most
relevant for clinical MDR. The traditional approach in targeting ABC
transporter as a strategy for overcoming MDR in chemotherapy involves
treatment with a combination of a cytotoxic anti-cancer agent and an
inhibitor of P-gp as drug sensitizer. However, clinical trials conducted
with P-gp inhibitors continued to yield negative outcomes, which lead to
a general skepticism on the feasibility of the MDR reversal approach
(Libby and Hromas, 2010; Tamaki et al., 2011). More recently, there is
a strong interest in exploiting collateral sensitivity in cancer cells, a
phenomenon in which drug resistant cells concomitantly develop
hypersensitivity to alternate drugs (Szakács et al., 2014; Genoux-Bastide
et al., 2011). Recent advances in the field have shown that collateral
sensitivity in tumors can be temporal and/or persistent due to the
dynamic nature of tumor clonal evolution and the sequential use of drugs
targeting dynamic tumor vulnerabilities can, therefore, be a promising
approach toward eliminating MDR (Colmegna et al., 2015; Zhao et al.,
2016). In the present study, we show that MRP1-overexpressing H69AR

and HEK293/MRP1 cells exhibit collateral sensitivity toward calcitriol
and calcipotriol. Although both H69AR and HEK293/MRP1 cell lines
over-express MRP1, the former was obtained under doxorubicin selection
and may have other physiologic changes as well, whereas the later was
obtained through stable transfection and likely purely expressing the
transporter without other physiologic changes. Interestingly, this phenomenon appears to be specific to MRP1-overexpressing cells as the sensitivity
was not observed in HEK293/P-gp or HEK293/BCRP cells. Furthermore,
we found that this collateral sensitivity can be eliminated by MRP1
inhibitor MK571. There could be various possibilities how calcitriol and
calcipotriol can be selectively cytotoxic to MRP1 over-expressing cells
including stimulation of GSH efflux, up-regulation of apoptosis in a
MRP1-dependant manner and assuming if these molecules are indeed
substrates of MRP1 then they may bind something which is essential for the
cell and the co-transport is toxic to cells (Laberge et al., 2007; Lorendeau
et al., 2014; Trompier et al., 2004). These data provide a framework for
further investigation into the use of vitamin D analogs in clinical chemotherapy, especially in cancers with prominent MRP1 expression, such as
primary neuroblastoma (Haber et al., 2006; Yan and Nuriding, 2014).
Calcitriol is a multifunctional hormone that exerts its activity through
the nuclear vitamin D receptor (VDR), which is a member of the nuclear
receptor superfamily of ligand-activated transcription factors. Recent
evidence has linked VDR to the upregulation of ABC transporter
expression. In Caco-2 cells, which are commonly used as a physiologic
barrier model for the small intestine, treatment with calcitriol activates
the expression of P-gp, MRP2, and MRP4 through VDR (Fan et al.,
2009). A study performed in conscious rats also reported that calcitriolinduced VDR activation increases cerebral P-gp expression and restricts
brain distribution of P-gp substrates (Durk et al., 2015). While the longer
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Fig. 8. Effects of calcitriol and calcipotriol on drug sensitivity of HEK293/P-gp and
HEK293/BCRP cells. HEK293/P-gp (A) and HEK293/BCRP (B) cells were treated
with increasing concentrations of vincristine and mitoxantrone, respectively, in the
absence and presence of calcitriol or calcipotriol (10 mM) for 72 hour. Verapamil
(25 mM) and Ko143 (1 mM) were used as positive controls in HEK293/P-gp and
HEK293/BCRP cells, respectively. HEK293/pcDNA cells were included as negative
control for drug resistance. Cell viability was evaluated with MTT assay. Data are
representative of three experiments and expressed as mean 6 S.D. (n = 3).
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TABLE 3
Effect of calcitriol and calcipotriol (10 mM) on IC50 of vincristine and mitoxantrone
in HEK293/P-gp and HEK293/BCRP, respectively
Verapamil (25 mM) and Ko143 (1 mM) are used as positive controls.
Cell line/Treatment

HEK293/pcDNA3.1
HEK293/P-gp (control)
HEK293/P-gp + verapamil
HEK293/P-gp + calcitriol
HEK293/P-gp + calcipotriol
HEK293/BCRP (control)
HEK293/BCRP + Ko143
HEK293/BCRP + calcitriol
HEK293/BCRP + calcipotriol

Vincristine, IC50 (nM)a

3.70
1394.00
2.95
758.93
982.60

6
6
6
6
6

1.26***
174.46
1.16***
323.48*
118.54

Mitoxantrone, IC50 (nM)a

4.57 6 1.48***

30.88
1.33
12.84
l29.66

6
6
6
6

4.18
0.14***
0.26**
3.21

a
Mean 6 S.E.M. of n = 3 independent experiments.
*P , 0.05; **P , 0.01; ***P , 0.001 significantly different then control in each treatment
group, calculated using linear mixed model with Sidak post hoc test.

(Nestle et al., 2009). Interestingly, keratinocyte proliferation is also
stimulated by LTC4, a high affinity substrate of MRP1, in a mouse model
of atopic dermatitis to promote hyperkeratosis and fibrosis (Oyoshi et al.,
2012). It will be of interest to investigate the probable involvement of
MRP1 in the pathogenesis of psoriasis, as inhibition of MRP1-mediated
efflux of inflammatory mediators could be a mechanism by which
calcipotriol exert its therapeutic effect. In our study calcipotriol treatment
at 1 and 10 mM did not affect the MRP1 protein levels in HEK293/MRP1
and H69AR cells whereas our results demonstrate a clear inhibitory effect
of calcipotriol on the efflux activity of MRP1, P-gp and BCRP.
In conclusion, this study brings a new perspective to the application
of calcitriol and its analogs in cancer treatment. Specifically, our work
suggests the potential use of calcitriol and its analogs in selectively
targeting tumors with the MDR phenotype conferred by MRP1 overexpression and provides the rational for sequential use of calcitriol and
other anti-cancer agents to circumvent the development of MRP1mediated MDR in clinical chemotherapy. Future work should be
focused on designing calcitriol analogs with improved potency and
validating the feasibility of applying the MRP1-selective effect of
calcitriol in vivo.
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